Suchergebnisse - "Dugel, Pravin U"

PubPharm (152)

1

A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration

enthalten in: Ophthalmology | 2023

von Jackson, T. | Slakter, J. | Buyse, M. | +108

2

EFFECT OF RETINAL THICKNESS VARIABILITY ON VISUAL OUTCOMES AND FLUID PERSISTENCE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION : A Post Hoc Analysis of the HAWK and HARRIER Studies

enthalten in: Retina (Philadelphia, Pa.) | 2022

von Dugel, P. | Jhaveri, C. | Chakravarthy, U. | +6

3

Complement cascade inhibition in geographic atrophy : a review

enthalten in: Eye (London, England) | 2022

von Desai, D. | Dugel, P.

4

Capillary density and caliber as assessed by optical coherence tomography angiography may be significant predictors of diabetic retinopathy severity

enthalten in: PloS one | 2022

von Kushner-Lenhoff, S. | Kogachi, K. | Mert, M. | +13

5

Phase 1 Dose-Escalation Study of Plasma Kallikrein Inhibitor THR-149 for the Treatment of Diabetic Macular Edema

enthalten in: Translational vision science & technology | 2021

von Dugel, P. | Khanani, A. | Berger, B. | +5

6

Phase 1 Study of THR-687, a Novel, Highly Potent Integrin Antagonist for the Treatment of Diabetic Macular Edema

enthalten in: Ophthalmology science | 2021

von Khanani, A. | Patel, S. | Gonzalez, V. | +6

7

HAWK and HARRIER : Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration

enthalten in: Ophthalmology | 2021

von Dugel, P. | Singh, R. | Koh, A. | +7

ErratumIn: Ophthalmology. 2022 May;129(5):593-596. - PMID 35461529

8

Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration : The AVENUE Phase 2 Randomized Clinical Trial

enthalten in: JAMA ophthalmology | 2020

von Sahni, J. | Dugel, P. | Patel, S. | +9

9

Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration : The STAIRWAY Phase 2 Randomized Clinical Trial

enthalten in: JAMA ophthalmology | 2020

von Khanani, A. | Patel, S. | Ferrone, P. | +7

CommentIn: JAMA Ophthalmol. 2020 Sep 1;138(9):972-973. - PMID 32729885

10

Brolucizumab : Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration

enthalten in: Ophthalmology | 2020

von Nguyen, Q. | Das, A. | Do, D. | +9

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[16]